Angelene M. Cantwell

Molecular mapping of thrombin-receptor interactions

In addition to its procoagulant and anticoagulant roles in the blood coagulation cascade, thrombin works as a signaling molecule when it interacts with the G‐protein coupled receptors PAR1, PAR3, and PAR4. We have mapped the thrombin epitopes responsible for these interactions using enzymatic assays and Ala scanning mutagenesis. The epitopes overlap considerably, and are almost identical to those of fibrinogen and fibrin, but a few unanticipated differences are uncovered that help explain the higher (90‐fold) specificity of PAR1 relative to PAR3 and PAR4. The most critical residues for the interaction with the PARs are located around the active site where mutations affect recognition in the order PAR4 > PAR3 > PAR1. Other important residues for PAR binding cluster in a small area of exosite I where mutations affect recognition in the order PAR1 > PAR3 > PAR4. Owing to this hierarchy of effects, the mutation W215A selectively compromises PAR4 cleavage, whereas the mutation R67A abrogates the higher specificity of PAR1 relative to PAR3 and PAR4. 3D models of thrombin complexed with PAR1, PAR3, and PAR4 are constructed and account for the perturbations documented by the mutagenesis studies. Proteins 2001;45:107–116.

The Thrombin Mutant W215A/ E217A Shows Safe and Potent Anticoagulant and Antithrombotic Effects in Vivo*

Administration of the thrombin mutant W215A/E217A (WE), rationally designed for selective activation of the anticoagulant protein C, elicits safe and potent anticoagulant and antithrombotic effects in a baboon model of platelet-dependent thrombosis. The lowest dose of WE tested (0.011 mg/kg bolus) reduced platelet thrombus accumulation by 80% and was at least as effective as the direct administration of 40-fold more (0.45 mg/kg bolus) activated protein C. WE-treated animals showed no detectable hemorrhage or organ failure. No procoagulant activity could be detected for up to 1 week in baboon plasma obtained following WE administration. These results show that engineered thrombin derivatives that selectively activate protein C may represent useful therapeutic agents for the treatment of thrombotic disorders.

Redesigning the monovalent cation specificity of an enzyme

Monovalent-cation-activated enzymes are abundantly represented in plants and in the animal world. Most of these enzymes are specifically activated by K+, whereas a few of them show preferential activation by Na+. The monovalent cation specificity of these enzymes remains elusive in molecular terms and has not been reengineered by site-directed mutagenesis. Here we demonstrate that thrombin, a Na+-activated allosteric enzyme involved in vertebrate blood clotting, can be converted into a K+-specific enzyme by redesigning a loop that shapes the entrance to the cation-binding site. The conversion, however, does not result into a K+-activated enzyme.

The Thrombin Epitope Recognizing Thrombomodulin Is a Highly Cooperative Hot Spot in Exosite I

The functional epitope of thrombin recognizing thrombomodulin was mapped using Ala-scanning mutagenesis of 54 residues located around the active site, the Na+ binding loop, the 186-loop, the autolysis loop, exosite I, and exosite II. The epitope for thrombomodulin binding is shaped as a hot spot in exosite I, centered around the buried ion quartet formed by Arg67, Lys70, Glu77, and Glu80, and capped by the hydrophobic residues Tyr76 and Ile82. The hot spot is a much smaller subset of the structural epitope for thrombomodulin binding recently documented by x-ray crystallography. Interestingly, the contribution of each residue of the epitope to the binding free energy shows no correlation with the change in its accessible surface area upon formation of the thrombin-thrombomodulin complex. Furthermore, residues of the epitope are strongly coupled in the recognition of thrombomodulin, as seen for the interaction of human growth hormone and insulin with their receptors. Finally, the Ala substitution of two negatively charged residues in exosite II, Asp100 and Asp178, is found unexpectedly to significantly increase thrombomodulin binding.

Determinants of Thrombin Specificity

Abstract: Thrombin recognizes a number of natural substrates that are responsible for important physiologic functions. Its high specificity is controlled by residues within the active site, and by separate recognition sites located on the surface of the enzyme. A number of studies have addressed the question of how thrombin changes its specificity from fibrinogen to protein C, switching from a procoagulant to an anticoagulant enzyme. Site directed mutagenesis studies have revealed important aspects of how this switch takes place. Specifically, residues W215 and E217 have emerged as key residues in controlling the interaction with fibrinogen in that mutation of these residues compromises the procoagulant function of the enzyme up to 500‐fold. The loss of fibrinogen clotting reaches 20,000‐fold in the double mutant W215A/E217A, whereas protein C activation is compromised less than sevenfold. These findings demonstrate that thrombin specificity can be dissected at the molecular level using Ala‐scanning mutagenesis and the procoagulant function of the enzyme can be abrogated rationally and selectively. It is now possible to extend this strategy to the study of other interactions of thrombin, as well as to related serine proteases.

Three-dimensional Models of Proteases Involved in Patterning of the Drosophila Embryo CRUCIAL ROLE OF PREDICTED CATION BINDING SITES

Three-dimensional models of the catalytic domains of Nudel (Ndl), Gastrulation Defective (Gd), Snake (Snk), and Easter (Ea), and their complexes with substrate suggest a possible organization of the enzyme cascade controlling the dorsoventral fate of the fruit fly embryo. The models predict that Gd activates Snk, which in turn activates Ea. Gd can be activated either autoproteolytically or by Ndl. The three-dimensional models of each enzyme-substrate complex in the cascade rationalize existing mutagenesis data and the associated phenotypes. The models also predict unanticipated features like a Ca2+ binding site in Ea and a Na+ binding site in Ndl and Gd. These binding sites are likely to play a crucial role in vivo as suggested by mutant enzymes introduced into embryos as mRNAs. The mutations in Gd that eliminate Na+ binding cause an apparent increase in activity, whereas mutations in Ea that abrogate Ca2+ binding result in complete loss of activity. A mutation in Ea predicted to introduce Na+ binding results in apparently increased activity with ventralization of the embryo, an effect not observed with wild-type Ea mRNA.